1. Meaning of Sponsor Indemnification

Indemnification is a contractual mechanism by which one party agrees to compensate another for specified losses, liabilities, claims, damages, costs or legal expenses arising from an identified risk.

In a clinical-trial agreement (“CTA”), the sponsor normally assumes responsibility for risks arising from:

• the investigational product;
• the design of the clinical-trial protocol;
• sponsor's instructions;
• sponsor's negligence or misconduct;
• trial-related injury or death falling within applicable regulatory compensation rules; and
• claims resulting from the sponsor's breach of law or contractual obligations.

The important distinction is between trial-related injury and professional malpractice/negligence by the investigator or institution.

A sponsor's indemnity normally should not automatically protect an investigator or hospital from liability for its own medical malpractice, negligence, wilful misconduct, fraud or protocol violations. Modern clinical-trial agreements therefore commonly contain an exclusion for claims caused by the investigator's or institution's negligence/malpractice.

This distinction is also reflected in international GCP principles: sponsor indemnification/insurance is generally contemplated for trial-related claims, while malpractice/negligence is treated separately.

2. Sponsor Indemnification vs. Malpractice

These concepts should be kept separate.

Sponsor indemnification

The sponsor says, in substance:

“If a third party brings a claim against the investigator or institution because of risks for which the sponsor is responsible, the sponsor will defend and compensate them.”

Medical malpractice

Malpractice arises where a doctor, investigator, hospital or research team fails to exercise the required standard of professional care.

Examples:

• administering the wrong dose;
• failing to monitor a participant;
• failing to respond appropriately to an adverse event;
• performing an unauthorised procedure;
• violating the approved protocol;
• failing to obtain valid informed consent;
• negligent medical treatment unrelated to the investigational product.

Thus, the fact that an injury occurs during a clinical trial does not necessarily mean that the sponsor must indemnify the investigator for the investigator's malpractice.

3. Indian Statutory Position

India has developed a specific regulatory framework for compensation arising from clinical-trial injuries.

Historically, Rule 122DAB of the Drugs and Cosmetics Rules, 1945 was particularly important. CDSCO itself identifies Rule 122DAB as dealing with serious adverse events involving injury/death and compensation.

The current framework is principally contained in the New Drugs and Clinical Trials Rules, 2019 (NDCTR 2019).

Rule 122DAB — historical significance

Under Rule 122DAB:

• the injured subject was entitled to free medical management;
• compensation could be payable for clinical-trial-related injury or death;
• the sponsor bore the expenses of medical management and financial compensation;
• the sponsor had to give an undertaking to provide compensation; and
• failure to provide compensation could lead to regulatory action against the sponsor. 

Most importantly, Rule 122DAB(5) treated injury/death as clinical-trial-related where, among other things, it resulted from:

1. adverse effects of the investigational product;
2. violation of the approved protocol;
3. scientific misconduct;
4. negligence by the sponsor, sponsor's representative or investigator;
5. failure of the investigational product to provide its intended therapeutic effect in specified circumstances;
6. certain placebo situations;
7. adverse effects from protocol-required concomitant medication;
8. injury to a child in utero; or
9. clinical-trial procedures. 

This is significant because negligence of the investigator could fall within the regulatory compensation regime.

4. Does Investigator Malpractice Automatically Become Sponsor Liability?

No—not necessarily.

This is one of the most important points.

There are potentially two different relationships:

A. Sponsor → Trial participant

The regulatory framework can impose a direct obligation on the sponsor to provide compensation for qualifying clinical-trial-related injury.

B. Sponsor → Investigator/institution

This is primarily a contractual indemnification relationship.

A CTA may say:

Sponsor indemnifies the investigator against claims arising from the investigational product or proper performance of the protocol.

But the clause may then exclude:

claims caused by the investigator's negligence, malpractice, wilful misconduct, fraud or violation of the protocol.

Consequently:

Participant may have a compensation claim against the sponsor even though the sponsor may have a contractual right to recover that amount from the investigator/institution where the injury resulted from the investigator's malpractice.

That is why the indemnification clause must be carefully drafted.

5. Example

Suppose a pharmaceutical company sponsors a Phase III trial.

The protocol requires:

Drug X — 10 mg once daily.

The investigator accidentally administers 100 mg to the participant.

The participant suffers serious injury.

There are two separate questions:

Question 1 — Is the participant entitled to compensation?

Potentially yes, because the injury may constitute a clinical-trial-related injury, particularly where it resulted from protocol violation or investigator negligence.

Question 2 — Can the investigator demand indemnification from the sponsor?

Not necessarily.

If the CTA says sponsor indemnification excludes investigator malpractice/negligence, the investigator cannot simply say:

“This happened during the clinical trial, therefore the sponsor must indemnify me.”

The sponsor can argue:

“The injury resulted from your own negligent administration of the drug, which is expressly excluded from our indemnity.”

This distinction is fundamental.

6. What Should a Sponsor Indemnity Clause Cover?

A well-drafted sponsor indemnity can cover claims arising from:

(a) Investigational product

For example:

• unexpected adverse drug reaction;
• product defect;
• contamination;
• manufacturing defect;
• pharmacological risk.

(b) Protocol design

If the sponsor designed an unsafe protocol and the institution followed it correctly, liability may properly rest with the sponsor.

(c) Sponsor's negligence

For example:

• failure to disclose known safety information;
• inadequate safety monitoring;
• failure to communicate an important safety warning;
• inaccurate investigator information.

(d) Sponsor's regulatory violations

For example:

• failure to comply with applicable regulatory requirements;
• failure to obtain necessary approvals;
• unlawful sponsor instructions.

(e) Trial-related participant claims

The sponsor may undertake to defend and indemnify the institution/investigator against specified claims brought by participants.

7. What Should Normally Be Excluded?

The sponsor should ordinarily negotiate exclusions for:

Investigator malpractice

Examples:

• negligent medical treatment;
• wrong dosage;
• failure to monitor;
• failure to diagnose;
• failure to treat;
• unauthorised medical procedure.

Wilful misconduct

The sponsor should not ordinarily indemnify deliberate wrongdoing.

Fraud

Fraudulent conduct should generally remain with the party responsible.

Protocol violation

If the investigator deliberately or negligently departs from the approved protocol, the sponsor may seek exclusion.

Failure to obtain informed consent

Where this is attributable to the investigator/site, the CTA may allocate responsibility to the investigator/institution.

Unauthorised use of investigational product

Again, responsibility may fall on the site.

8. Important Indian Case Law

There is limited reported Indian judicial precedent directly deciding the precise question of “whether sponsor indemnification covers investigator malpractice.” Therefore, it is important not to cite unrelated medical-negligence cases as though they directly decide clinical-trial indemnity.

However, several cases and proceedings are highly relevant.

A. Swasthya Adhikar Manch, Indore v. Union of India

This Supreme Court litigation is one of the most important authorities concerning clinical-trial regulation in India.

The PIL concerned alleged irregularities in clinical trials, including concerns about:

• informed consent;
• participant safety;
• compensation for injury/death;
• regulatory oversight; and
• approval and monitoring of clinical trials.

The Supreme Court's intervention contributed to significant strengthening of India's clinical-trial regulatory framework.

The proceedings continued over a number of years; the Supreme Court record also reflects the subsequent enactment of the New Drugs and Clinical Trials Rules, 2019.

Legal significance

The case demonstrates that clinical-trial participants are not merely contractual parties whose rights depend exclusively upon a CTA.

Participant protection has a strong regulatory/public-law dimension.

Therefore, a sponsor cannot rely on a private indemnity clause to contract out of mandatory statutory obligations toward trial participants.

9. Pfizer Ltd., Mumbai v. Assessee — Contractual Indemnity

An especially useful Indian authority for understanding the structure of indemnification in clinical-trial arrangements is the litigation involving Pfizer.

The case concerned agreements relating to clinical-trial/data-management activities.

The agreement contained a reciprocal risk-allocation structure:

• the overseas entity agreed to indemnify the Indian entity for specified liabilities arising from clinical trials;
• that protection did not extend to losses resulting from the Indian entity's failure to perform its obligations properly, negligence, wilful misconduct, wrongful acts or regulatory non-compliance;
• conversely, the Indian entity had indemnification obligations toward Pfizer in relation to its own failures/negligence/misconduct. 

Why this case is important

It illustrates the commercial principle behind a CTA:

Each party bears risks attributable to its own misconduct/negligence, while the sponsor/group company bears specified risks inherent in the clinical-trial activity.

Although the litigation arose in a tax context rather than as a participant-malpractice claim, the contractual indemnity provisions are highly instructive when analysing how clinical-trial parties allocate risk.

10. Parexel International Clinical Research Pvt. Ltd. Case

Another useful Indian decision is the litigation involving Parexel.

The agreement contained an undertaking under which one group entity indemnified the Indian entity against liabilities arising from performance of the clinical-trial services.

The tribunal recognised the commercial significance of the indemnity because clinical-trial services involve substantial risks, including regulatory failures and potential injury.

Principle

The case supports the proposition that:

Indemnification in clinical-trial contracts is a genuine allocation of commercial and regulatory risk rather than merely boilerplate contractual language.

11. ACIT v. Pfizer Ltd. and Similar Contractual Cases

The Pfizer litigation also demonstrates an important drafting principle:

The indemnity is generally conditional.

In other words:

Sponsor indemnifies the site for specified clinical-trial liabilities, except where the loss resulted from the site's own negligence, misconduct, wrongful act or regulatory breach.

This is substantially different from an unlimited:

“Sponsor shall indemnify the investigator against all claims arising out of the clinical trial.”

The latter can inadvertently transfer malpractice risk to the sponsor.

12. Relationship Between Malpractice and Clinical-Trial Injury

A useful way to understand the issue is through a four-part distinction:

The last category is particularly difficult.

Example

Suppose:

• Drug X causes a known risk of cardiac toxicity;
• the protocol requires ECG monitoring every 48 hours;
• the investigator fails to perform the required monitoring;
• the participant suffers cardiac injury.

The sponsor may argue:

“The drug's adverse effect is covered.”

The investigator may argue:

“The drug caused the injury.”

The participant may argue:

“The injury became serious because the investigator failed to monitor me.”

This could create concurrent causation.

The ultimate allocation of liability would depend on:

• applicable statute;
• facts;
• medical evidence;
• protocol;
• informed consent;
• CTA;
• indemnity wording;
• insurance policy;
• regulatory findings; and
• applicable principles of negligence and causation.

13. Sponsor's Statutory Obligation Cannot Simply Be Contracted Away

This is extremely important.

Suppose a CTA says:

“Sponsor shall have no responsibility whatsoever for any injury suffered by a clinical-trial subject.”

That contractual clause cannot automatically eliminate mandatory statutory/regulatory obligations.

Under the historical Rule 122DAB framework, the sponsor was expressly required to bear medical-management expenses and compensation for qualifying clinical-trial injury/death.

Likewise, the sponsor had to provide an undertaking concerning compensation, and regulatory authorities could take action if the sponsor failed to comply.

Therefore:

Private contractual allocation ≠ elimination of statutory liability.

A sponsor may potentially seek contractual recourse against an investigator who caused the loss, but that is a different question from the sponsor's initial regulatory responsibility to the participant.

14. Indemnity and Insurance Are Different

This distinction is often examined in legal examinations.

Indemnity

A contractual promise to compensate for specified losses.

Insurance

A risk-financing mechanism under which an insurer assumes specified risks in return for a premium.

Thus:

Indemnity allocates the risk; insurance funds the risk.

A sponsor may have:

1. a contractual indemnity in the CTA;
2. clinical-trial liability insurance;
3. product liability insurance; and
4. other corporate insurance.

The existence of insurance does not necessarily determine whether an indemnity clause exists.

15. Model Sponsor Indemnity Clause

A balanced clause could read approximately as follows:

Model Sponsor Indemnification Clause — Clinical Trial

The Sponsor shall indemnify, defend and hold harmless the Institution, Principal Investigator and members of the study team from and against claims, liabilities, damages, losses, reasonable legal expenses and costs arising out of or relating to the Clinical Trial, to the extent that such claims result from:

(a) the use or administration of the Investigational Product in accordance with the approved Clinical Trial Protocol;

(b) adverse effects or risks attributable to the Investigational Product;

(c) defects in the Investigational Product or information supplied by the Sponsor;

(d) the Sponsor's negligence, wilful misconduct or violation of applicable law; or

(e) the Sponsor's material breach of the Clinical Trial Protocol or its obligations under this Agreement.

The Sponsor's indemnification obligation shall not apply to the extent that a claim, loss or liability is caused by the negligence, malpractice, wilful misconduct, fraud, unauthorised acts, material protocol deviation or violation of applicable law by the Institution, Principal Investigator or members of the study team.

Nothing in this Agreement shall limit or exclude any mandatory obligation of the Sponsor to provide medical management or compensation to a clinical-trial subject where such obligation arises under applicable law or regulatory requirements.

Where a loss results from the concurrent acts or omissions of the Sponsor and the Institution or Principal Investigator, liability and indemnification shall, to the extent legally permissible, be allocated according to the respective contribution to the loss.

The Sponsor shall maintain appropriate clinical-trial liability insurance for the duration of the Clinical Trial and shall provide evidence of such insurance upon reasonable request by the Institution.

16. Why This Clause Is Better

This drafting approach prevents two opposite problems.

Problem 1 — Overly broad sponsor indemnity

If the sponsor indemnifies against “all claims arising out of the clinical trial,” it may inadvertently assume responsibility for:

• doctor negligence;
• malpractice;
• fraud;
• protocol violations;
• unauthorised procedures.

Problem 2 — Overly narrow sponsor indemnity

If the sponsor excludes virtually everything, the institution may be left exposed to risks that are fundamentally the sponsor's responsibility, such as:

• adverse effects of the investigational product;
• defective product;
• unsafe protocol design;
• sponsor negligence.

A good CTA therefore follows the principle:

Sponsor bears sponsor risk; investigator bears investigator malpractice risk; mandatory statutory participant protections remain enforceable.

17. Important Principle: Participant's Rights vs. Investigator's Indemnity

This distinction deserves special emphasis.

There are three parties:

Sponsor → Investigator/Institution → Trial Participant

The CTA primarily governs the relationship between sponsor and investigator/institution.

The participant's rights, however, may arise independently from:

• statute;
• clinical-trial regulations;
• informed consent;
• tort/medical-negligence principles;
• constitutional/public-law protections in appropriate cases; and
• other applicable laws.

Therefore, the sponsor cannot necessarily say:

“Our CTA says the investigator is responsible, so the participant must sue the investigator.”

That may not defeat a regulatory compensation obligation imposed on the sponsor.

Conversely, the investigator cannot necessarily say:

“The sponsor is responsible for the trial, therefore my malpractice is indemnified.”

The two questions must be analysed independently.

18. New Drugs and Clinical Trials Rules, 2019

The NDCTR 2019 replaced the older framework for new drugs and clinical trials and contains specific provisions dealing with clinical-trial permissions, ethics committees, compensation and related matters. CDSCO publishes the Rules and subsequent amendments on its official regulatory portal.

The Rules also prescribe formulas for determining compensation in cases of clinical-trial-related injury or death. The Seventh Schedule, for example, provides a formula for death based on a base amount, age-related factor and risk factor.

This is important because compensation is not simply left to whatever amount a sponsor happens to negotiate privately with an investigator.

19. Case-Law Principle in One Sentence

The authorities collectively support the following proposition:

Clinical-trial participants must receive the protection required by applicable regulatory law; contractual indemnification allocates financial risk between sponsor and investigator/institution, but normally does not convert the investigator's own malpractice into the sponsor's contractual liability unless the agreement expressly provides otherwise.

20. Conclusion

Sponsor indemnification for malpractice in clinical trials is fundamentally a question of risk allocation.

The sponsor generally assumes responsibility for risks inherent in the investigational product, protocol and sponsor's own conduct. The investigator and institution generally remain responsible for their own professional negligence, malpractice, wilful misconduct, fraud and unauthorised or material protocol violations, subject to the exact contractual language and applicable law.

At the same time, participant compensation is a separate regulatory issue. India's clinical-trial regime has imposed significant obligations on sponsors concerning medical management and compensation for qualifying trial-related injuries and deaths. The Supreme Court's intervention in Swasthya Adhikar Manch v. Union of India is particularly important in understanding the development of this participant-protection framework.

The most important practical rule is therefore:

“Indemnity between contracting parties does not necessarily determine the participant's statutory right to compensation.”

For an Indian clinical-trial agreement, the indemnity clause should consequently distinguish (1) sponsor/product/protocol risk, (2) investigator malpractice, (3) shared or concurrent negligence, and (4) mandatory statutory compensation obligations.